 | |
| Clinical data | |
|---|---|
| Trade names | Braftovi |
| Other names | LGX818 |
| AHFS/ Drugs.com | Monograph |
| MedlinePlus | a618040 |
| License data |
|
|
Routes of administration | By mouth |
| Drug class | BRAF kinase inhibitor [1] |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C22H27ClFN7O4S |
| Molar mass | 540.01 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
Encorafenib, sold under the brand name Braftovi, is a medication used to treat melanoma and colorectal cancer. [2] Specifically it is used for cases which are BRAF V600E or V600K mutation-positive that cannot be removed by surgery. [2] It is taken by mouth. [1]
Common side effects include tiredness, nausea, diarrhea,, abdominal pain, rash, and joint pain. [2] Other side effects may include bleeding, uveitis, QT prolongation, and other cancers. [2] In those with minor liver problems a lower dose should be used. [3] Use in pregnancy may harm the baby. [2] It is a kinase inhibitor that blocks the BRAF protein. [2] [4]
Encorafenib was approved for medical use in the United States and Europe in 2018. [1] [4] In the United Kingdom for 4 weeks it costs the NHS about £5,600 as of 2021. [3] In the United States this amount costs about 12,400 USD. [5]
- ^ a b c "Encorafenib Monograph for Professionals". Drugs.com. Archived from the original on 20 July 2021. Retrieved 15 December 2021.
- ^ a b c d e f g h i "DailyMed - BRAFTOVI- encorafenib capsule". dailymed.nlm.nih.gov. Archived from the original on 21 April 2021. Retrieved 15 December 2021.
- ^ a b BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1023. ISBN 978-0857114105.
- ^ a b "Braftovi". Archived from the original on 16 September 2021. Retrieved 15 December 2021.
- ^ "Braftovi Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 19 April 2021. Retrieved 15 December 2021.
|
| |
| Clinical data | |
|---|---|
| Trade names | Braftovi |
| Other names | LGX818 |
| AHFS/ Drugs.com | Monograph |
| MedlinePlus | a618040 |
| License data |
|
|
Routes of administration | By mouth |
| Drug class | BRAF kinase inhibitor [1] |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C22H27ClFN7O4S |
| Molar mass | 540.01 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
Encorafenib, sold under the brand name Braftovi, is a medication used to treat melanoma and colorectal cancer. [2] Specifically it is used for cases which are BRAF V600E or V600K mutation-positive that cannot be removed by surgery. [2] It is taken by mouth. [1]
Common side effects include tiredness, nausea, diarrhea,, abdominal pain, rash, and joint pain. [2] Other side effects may include bleeding, uveitis, QT prolongation, and other cancers. [2] In those with minor liver problems a lower dose should be used. [3] Use in pregnancy may harm the baby. [2] It is a kinase inhibitor that blocks the BRAF protein. [2] [4]
Encorafenib was approved for medical use in the United States and Europe in 2018. [1] [4] In the United Kingdom for 4 weeks it costs the NHS about £5,600 as of 2021. [3] In the United States this amount costs about 12,400 USD. [5]
- ^ a b c "Encorafenib Monograph for Professionals". Drugs.com. Archived from the original on 20 July 2021. Retrieved 15 December 2021.
- ^ a b c d e f g h i "DailyMed - BRAFTOVI- encorafenib capsule". dailymed.nlm.nih.gov. Archived from the original on 21 April 2021. Retrieved 15 December 2021.
- ^ a b BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1023. ISBN 978-0857114105.
- ^ a b "Braftovi". Archived from the original on 16 September 2021. Retrieved 15 December 2021.
- ^ "Braftovi Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 19 April 2021. Retrieved 15 December 2021.